News
IVBXF
11.55
NaN%
--
Innovent Biologics (IVBXF) Gets a Buy from CLSA
TipRanks · 07/17 00:25
UOB Kay Hian Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
TipRanks · 07/16 07:27
UBS Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
TipRanks · 07/16 00:27
Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B
Seeking Alpha · 07/14 12:28
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
TipRanks · 07/14 10:11
HSBC Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 07/14 00:27
Zhongtai Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
TipRanks · 07/11 14:35
Nomura Remains a Buy on Innovent Biologics (IVBXF)
TipRanks · 07/11 00:25
UBS Keeps Their Buy Rating on Innovent Biologics (IVBXF)
TipRanks · 07/03 00:25
Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement
TipRanks · 06/30 09:50
Innovent, Eli Lilly partner to commercialize Verzenios in China
Seeking Alpha · 06/30 06:03
Innovent Biologics Shareholders Approve All AGM Resolutions, Strengthening Capital Flexibility
TipRanks · 06/24 22:38
Innovent Biologics Details Board and Committee Structure to Strengthen Governance
TipRanks · 06/24 22:37
Innovent Biologics Grants Share Options and Restricted Shares to Employees Under 2024 Scheme
TipRanks · 06/15 14:40
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Seeking Alpha · 06/10 19:19
Innovent Biologics (IVBXF) Receives a Buy from UBS
TipRanks · 06/10 00:26
Innovent Biologics (IVBXF) Receives a Buy from CICC
TipRanks · 06/04 09:15
Innovent’s Gastric Cancer ADC Wins China Priority Review After Phase 3 Success
TipRanks · 06/04 08:41
Innovent Biologics (IVBXF) Gets a Buy from BOCOM International Holdings Company
TipRanks · 06/04 05:25
Morgan Stanley Keeps Their Buy Rating on Innovent Biologics (IVBXF)
TipRanks · 06/04 00:25
More
Webull provides a variety of real-time IVBXF stock news. You can receive the latest news about Innovent Biologi through multiple platforms. This information may help you make smarter investment decisions.
About IVBXF
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.